Qiagen

Qiagen has published its financial results for the second quarter of 2012, during which it experienced a strong increase in sales.

The company's net sales rose by nine percent year on year to reach a total of $307.2 million (197.67 million pounds), with growth observed across all regions and customer classes.

Molecular diagnostics and applied testing product sales were noted as being particularly robust, while the firm was also able to expand through the acquisition of Cellestis, Ipsogen and AmniSure.

human-genome-sciences

GlaxoSmithKline plc (LSE: GSK) today announced that it has completed its acquisition of Human Genome Sciences (NASDAQ: HGSI) for US$3.6 billion on an equity basis, or approximately US$3 billion net of cash and debt. All outstanding shares of HGS were acquired for US$14.25 per share in cash.  

The subsequent offering period for GSK’s tender offer for HGS shares expired at 5:00 pm, New York City time, on 2 August 2012.  The depositary for the tender offer has advised GSK that approximately 174,430,970 shares were validly tendered and not withdrawn during the initial and subsequent offering periods (including shares that had been tendered by notice of guaranteed delivery and subsequently delivered), all of which have been accepted for payment and purchased.  Such shares, together with shares otherwise beneficially owned by GSK, represent a total of approximately 87% of HGS’ outstanding shares.

pres-log-md

What do I do after I graduate? That is never an easy question, but the July 19 Diamondback article, “Students struggle to find jobs after graduating with Ph.D.s in sciences,” suggests it might be even harder to figure out.

The article cited a recent survey showing 45 percent of computer, mathematical and natural sciences school graduates had accepted full-time employment after graduation. It stated, “CMNS Associate Dean Robert Infantino said job shortages coincide with the health of the economy and that the government must increase its investments in research and technology.”

itec-talk

A Review of the Federal Government's Entrepreneurial Initiatives
Monday, August 13, 12:00 pm to 12:30pm ET

Richard Bendis and Nish Acharya will talk about the innovation and entrepreneurship programs in Federal Government today. Nish will also discuss briefly the status of the EDA i6 competition and the noticeable increase in the quality of the proposals.

They will speak about the paradigm shift in the EDA programs from a "Bricks and Mortar" focus (hard) to a more innovative programmatic focus (soft) on innovation, commercialization and entrepreneurship.

They will also discuss the convergence of Universities, Government/ NIST and industry in the formation of private/public/partnerships to implement strategic innovation based economic development initiatives on a regional basis.

healthtech

If you thought buying stock in mobile health (mHealth) companies was a good idea, it is. But if you decided to invest in the overall digital health sector - which includes mHealth, B2B apps and consumer services such as ZocDoc – you’d be brilliant. And, probably very rich.

Private financing by venture capitalists more than tripled in the first half of 2012, according to a study by financial services company Burrill & Company, as reported by Richard MacManus at ReadWriteWeb. This follows a June report from nonprofit foundation Rock Health that showed "skyrocketing" VC funding in the healthcare sector.

Incubator

Did you know that the first business incubator was started in Batavia, N.Y., in 1956? Joseph Mancuso was the founder, and after seeing newly hatched chicks running around from one of his portfolio companies, he coined the business “incubator”. From there on out business incubators started gaining popularity. There are currently 1,200 in the U.S. They have caught the attention of local governments and universities interested in retaining entrepreneurial talent. An example of this is LaunchHouse’s partnership with the city of Shaker Heights.

watkins-human-genome

GlaxoSmithKline PLC has removed all of the executive officers of Human Genome Sciences Inc. as part of its $3.6 billion acquisition of the Rockville-based biotech, including President and CEO Tom Watkins.

GlaxoSmithKline PLC has removed all of the executive officers of Human Genome Sciences Inc. as part of its $3.6 billion acquisition of the Rockville-based biotech, including President and CEO Tom Watkins, according to a securities filing on Monday.

Whether Glaxo would keep the local company's management in place was the subject of great speculation after the buyout was announced earlier this month. Watkins, who had helmed the Maryland drugmaker since 2004, has been replaced by Deirdre Connelly, GSK's president of North America Pharmaceuticals.

scheer-partners

Scheer Partners Inc. and The JBG Cos. are reviving a $100 million real estate fund they established in 2008 to invest in life science properties.

Rockville-based Scheer, a broker for biotech and medical real estate, and the Chevy Chase developer had set up the Greater Washington Life Sciences Fund just as the recession kicked into gear. After buying one 53,000-square-foot property at 21 Firstfield Road in Gaithersburg, the partnership essentially went into hibernation.

Bohealth innovations

County Executive Ike Leggett (center) and Councilmembers Nancy Floreen (second from right) and Hans Riemer (right) visited BioHealth Innovation's Open House on July 23. BioHealth Innovation (BHI) was established as a public-private partnership to accelerate the technology transfer and commercialization of biohealth research in the Central Maryland region. At the event were BHI Chairman Scott Carmer (left) and CEO Rich Bendis (second from left).

I was happy to help celebrate the opening of the BioHealth Innovation’s new headquarters at the historic Wire Hardware Building in Rockville. BHI was established as a public-private partnership to accelerate the technology transfer and commercialization of biohealth research in Maryland, and that’s a great thing for Montgomery County. Congratulations BHI. We're glad to have you in Rockville.

-Nancy Floreen, Montgomery County Council Member

Maryland

Technology job openings surged by 8.2% in June, according to job-search site SimplyHired, but some places remain better than others if you’re looking for a tech job. The site's top and bottom five contain a few surprises.

SimplyHired bases its ranking on the number of tech job openings compared to the number of people who are working in the region. The numbers below are based on metropolitan areas as defined by the U.S. census bureau.

1. Baltimore, Maryland (46,150 people employed, 14,093 tech job openings): Hunter Sherman, the chief engineer at Sparks, Maryland-based BizBrag, Inc., said the company is struggling to find qualified people to fill its jobs. As a result, BizBrag is planning to move. “A big part of our issue is that we're just north of the city, and a majority of the engineers are located to the south, closer to the D.C. area,” Sherman said. “This is one of the major reasons that we plan on moving our business into the city in the coming months.”

Md bio enterprise

Admit it. You enjoy working in science, but weren’t always captivated by how it was taught. You aren't alone. Studies show that when students lose interest in science coursework the problem is often how science is taught - not science itself. Teachers lack the interesting curriculum and adequate support needed to provide engaging and intriguing coursework. The lack of interest among science students leaves them disinterested, bored, and unprepared to meet the challenges of a technology-driven future.

These findings have real-world consequences. Despite the heroic efforts of talented U.S. science teachers, many of our brightest young students migrate away from the science, technology, engineering, and math (STEM) career paths that could power America's 21st century competitiveness.

Biotechs

If you’ve recently asked yourself, or someone standing next to you, “Where are all the biotech jobs?” it’s a good thing you’re reading this now.

While surveying for our latest annual Top 25 List of biotechnology companies in the Baltimore area, I asked each company whether they’re hiring any time soon, and all of these below said yes:

nvca-yearbook-2012.png

The 2012 NVCA Yearbook includes a comprehensive analysis of U.S. venture capital industry statistics. The main source of data for this publication is ThomsonONE.com, the online research database of Thomson Reuters. ThomsonONE.com  is endorsed by the NVCA as the official United States venture capital activity database. The publication includes metrics regarding commitments made to venture capital funds, venture capital investments into entrepreneurial companies, and venture-backed exits (mergers and acquisitions and IPOs). The publication also includes appendices regarding portfolio company valuation guidelines, international accounting convergence and venture capital activity outside the United States.

biofactura-screen

Noble Life Sciences, Inc., a preclinical drug development contract research organization (CRO), announced a partnership with BioFactura, Inc. (Rockville, MD), a developer and provider of proprietary technologies and services for production of biologicals.

The collaboration expands Noble’s CRO services to include the development and production of monoclonal antibody and other protein-based drugs. Through the partnership, Noble becomes the exclusive commercial contract services provider of BioFactura’s technologies and capabilities.

davidmott

Chevy Chase-based New Enterprise Associates has closed on what appears to be the largest venture fund in history at $2.6 billion, the firm announced Wednesday.

NEA’s 14th fund gives the VC titan a fresh pool of capital to inject into tech companies along a wide array of stages, sectors and geographies, and comes two and a half years after the firm closed on a thirteenth fund that was only slightly less mammoth. NEA is among the most prolific startup funders in the D.C. region, both in biotech and information technology.